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Summary
Background—Release of serotonin and activation of serotonin 5HT2A receptors on platelet
surfaces is a potent augmentative stimulus for platelet aggregation. However, earlier-generation
serotonin receptor antagonists were not successfully exploited as antiplatelet agents, possibly
owing to their lack of specificity for the 5HT2A receptor subtype.
Objective—To assess whether targeted inhibition of the serotonin 5HT2A receptor attenuates
recurrent thrombosis and improves coronary patency in an in vivo canine model mimicking
unstable angina.
Methods—In protocol 1, anesthetized dogs were pretreated with a novel, selective inverse
agonist of the 5HT2A receptor (APD791) or saline. Recurrent coronary thrombosis was then
initiated by coronary artery injury + stenosis, and coronary patency was monitored for 3 h.
Protocol 2 was similar, except that: (i) treatment with APD791 or saline was begun 1 h after the
onset of recurrent thrombosis; (ii) template bleeding time was measured; and (iii) blood samples
were obtained for in vitro flow cytometric assessment of platelet responsiveness to serotonin.
Results—APD791 attenuated recurrent thrombosis, irrespective of the time of treatment: in both
protocols, flow–time area (index of coronary patency; normalized to baseline coronary flow)
averaged 58–59% (P < 0.01) following administration of APD791 vs. 21–28% in saline controls.
Moreover, the in vivo antithrombotic effect of APD791 was not accompanied by increased
bleeding, but was associated with significant and selective inhibition of serotonin-mediated
platelet activation.
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Conclusion—5HT2A receptor inhibition with APD791, even when initiated after the onset of
recurrent thrombosis, improves coronary patency in the in vivo canine model.
Keywords
angina; platelets; serotonin; thrombosis
The pathogenesis of platelet-mediated coronary artery thrombosis is complex, with multiple
in vivo agonists playing important causal and contributory roles [1,2]. Current clinical
therapies target either cyclo-oxygenase 1, the ADP P2Y12 receptor, or the glycoprotein (GP)
IIb/IIIa receptor [3]. However, these therapies, even in combination, are not fully effective
in preventing major thrombotic events [3], and are associated with an increase in bleeding
[4].
Release of serotonin from platelet dense granules and activation of serotonin receptors on
platelet surfaces has long been recognized to serve as a potent augmentative stimulus for
platelet aggregation [5–8]. Clinical application of serotonin receptor antagonists for the
prevention of thrombotic coronary events has, however, been confounded by their lack of
selectivity for the 5HT2A receptor (i.e. the serotonin receptor subtype expressed on platelets)
[9,10]. Accordingly, our aim was to assess the efficacy of APD791 (Arena Pharmaceuticals,
Inc., San Diego, CA, USA), a newly developed, potent and highly selective inverse agonist
of the 5HT2A receptor [9], in a well-established preclinical canine model of recurrent
thrombosis mimicking unstable angina [11–15]. Our specific goals were to: (i) establish
whether pretreatment with APD791 improves subsequent coronary patency; (ii) investigate
whether the efficacy of APD791 is maintained when the agent is administered after the onset
of recurrent thrombosis; (iii) show that APD791 acts on platelets in vivo and inhibits
serotonin-mediated platelet aggregation; and (iv) investigate whether APD791 exacerbates
bleeding.
Materials and methods
This study was approved by the Institutional Animal Care and Use Committee of the
University of Massachusetts Medical School, and conducted in accordance with the Guide
for the Care and Use of Laboratory Animals (1996).
Surgical preparation
Twenty-six adult mongrel dogs (weight: 12–14 kg) were anesthetized with intravenous
sodium pentobarbital (30 mg kg−1), intubated, and mechanically ventilated. Catheters were
inserted in the left jugular vein for administration of fluids and supplemental anesthesia, and
in the left carotid artery for measurement of heart rate and arterial pressure and collection of
blood samples. After exposure of the heart through a left lateral thoracotomy, two adjacent
segments of the left anterior descending coronary artery (LAD) were isolated, usually
midway along its course: a Doppler flow probe (Transonic Systems, Inc., Ithaca, NY, USA)
was applied to the distal LAD segment for continuous measurement of mean coronary blood
flow (CBF), and the proximal segment served as the site of later injury + stenosis. Arterial
pressure and CBF were monitored throughout each experiment, using a Micro-Med data
acquisition system.
Protocol 1: APD791 pretreatment
Study design—To address our first aim (i.e. investigate whether pretreatment with
APD791 attenuates recurrent coronary thrombosis), we randomly assigned 14 dogs to
receive: (i) APD791 − 0.07 mg kg−1 intravenous bolus (dissolved in 1 mL of saline),
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followed by a continuous intravenous infusion of 1.16 µg kg min−1 (volume of 100 µL
min−1) for the remainder of the protocol; or (ii) a volume-matched bolus + infusion of saline
(control; n = 7 per group; Fig. 1).
At 15 min after the onset of treatment, the isolated LAD segment was squeezed with
forceps, and a micromanometer constrictor was positioned around the site of injury and
tightened such that mean CBF was reduced to approximately 35% of its baseline value. This
triggers the development of cyclic variations in coronary blood flow (CFVs) caused by
platelet activation–aggregation, and the resultant spontaneous accumulation/dislodgement of
platelet-rich thrombi at the site of injury + stenosis (Fig. 2) [11–15]. CBF was then
monitored for 3 h without further intervention.
At the end of the 3-h observation period, cardiac arrest was produced under deep anesthesia
by intracardiac injection of KCl. As the severity of arterial injury is recognized to be a
crucial determinant of patency in this model [11,14–17], the damaged LAD segment was
collected from all dogs and stored in 10% neutral buffered formalin for later histologic
evaluation.
Endpoints and analysis—Heart rate and mean arterial pressure were recorded at
baseline (before randomization), during the initial 15 min after administration of APD791 or
saline, and throughout the 3-h observation period following injury + stenosis. In addition,
CBF was tabulated at baseline, during the 15 min after treatment, and immediately upon
application of the stenosis (before the onset of CFVs).
Histologic analysis of all damaged and stenotic LAD segments was performed by one
investigator (PW) without knowledge of the treatment group. Cross-sections (5 µm in
thickness) were cut from each artery and stained with picrosirius red (to facilitate specific
visualization of collagen fibers). For each vessel, the severity of injury was assigned a
semiquantitative score: 1 = endothelial denudation with little or no damage to the tunica
media; 2 = tears and dissections in the media, without exposure of the tunica adventitia; 3 =
loss of media and/or deep tears, with focal points of adventitial exposure totaling < 10% of
the arterial circumference; and 4 = loss of media with confluent and extensive (> 10%)
adventitial exposure [14–17].
Plasma APD791 levels were measured in all dogs at baseline (before randomization), at 10
min after the onset of treatment, and at 1 h and 2 h poststenosis (1.25 h and 2.25 h after the
start of treatment: Fig. 1). At each time-point, citrated blood samples were obtained and
centrifuged at 1500 ×g for 15 min, and the plasma was frozen and stored at − 80 °C for
quantitation of APD791 concentration [9].
Vessel patency during the 3 h following injury + stenosis was assessed by quantifying two
variables: the duration (in minutes) of total thrombotic occlusion (CBF = 0); and percentage
flow–time area, defined as the area of the flow–time tracing normalized for each dog to the
baseline coronary flow × 180 min [14,15,17].
Statistics—Hemodynamics, CBF and plasma APD791 levels were compared by two-
factor ANOVA (for group and time) with replication, and, if significant F-values were obtained,
post hoc pairwise comparisons were made using the Newman–Keuls test. Zero flow
duration, percentage flow–time area and arterial injury scores were compared between saline
and APD791-treated groups by t-tests. All data are reported as means ± standard errors of
the mean (SEMs), and P-values < 0.05 are considered to be statistically significant.
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Protocol 2: APD791 ‘delayed’ treatment
Study design—To address our three remaining aims (determine whether administration of
APD791 after the onset of recurrent thrombosis inhibits CFVs, show that APD791 acts on
platelets in vivo and inhibits serotonin-induced platelet activation, and assess whether
APD791 exacerbates bleeding), we subjected 12 additional dogs to coronary artery injury +
stenosis, as described for protocol 1. After CBF had been monitored for 1 h, dogs received
either: (i) APD791 at the same dose (bolus + infusion) administered in protocol 1; or (ii)
saline. CBF was monitored for an additional 2 h after the onset of treatment (n = 6 per
group).Template bleeding time, ex vivo serotonin-stimulated platelet function and plasma
APD791 concentrations were assessed in all dogs at three time-points: before injury +
stenosis (baseline), immediately before randomization and treatment (i.e. at 1 h after the
onset of CFVs), and at 1.5 h after the start of APD791 or saline administration (Fig. 1). At
the end of the 3-h observation period, animals were killed, and the damaged LAD segments
were harvested for histologic evaluation.
Endpoints and analysis—Heart rate and mean arterial pressure were recorded at
baseline and throughout the 3-h observation period; CBF was tabulated at baseline and after
application of the stenosis.
Histologic analysis of the LAD at the site of injury + stenosis and quantitation of plasma
APD791 levels were conducted as in protocol 1.
Vessel patency was quantified by measuring zero flow duration and flow–time area as
described for protocol 1. In this case, however, data obtained during the 1-h pretreatment
phase were normalized and expressed as a percentage of baseline coronary flow × 60 min,
whereas results obtained during the 2-h post-treatment period were normalized and
expressed as a percentage of baseline flow × 120 min.
Template bleeding times were assessed from standardized incisions made on the anterior
surface of the tongue (Surgicutt automated incision-making instrument: incisions 1 mm in
depth and 5 mm in length; ITC, Edison, NJ, USA). Blood was wicked onto preweighed
blotting paper at 20-s intervals, and bleeding times were calculated as the time from making
of the incision until transfer of blood to the blotting paper ceased [18]. In addition, shed
blood ‘volumes’ were estimated by allowing the blotting paper obtained at each sample
period to dry for 24 h, reweighing, and calculating the difference in blotting paper weight
after vs. before the bleeding time test.
APD791 inhibition of ex vivo serotonin-stimulated platelet function was assessed from
citrated blood samples collected at each of the three sample times. Two assays were
performed. For detection of serotonin-stimulated F-actin polymerization (assessed by
phalloidin binding), blood was diluted 1 : 4 in HEPES–Tyrode’s buffer, stimulated for 25 s
at 22 °C with 1 µM serotonin, fixed with 1% ultrapure formaldehyde, and diluted 1 : 20 in
HEPES–Tyrode’s buffer. The samples were then permeabilized with 0.1% Triton X-100 and
stained with Alexa Fluor 488-conjugated phalloidin (500 nM; Invitrogen Molecular Probes,
Carlsbad, CA, USA) and, as a platelet identifier, phycoerythrin (PE)-conjugated CD41
(DAKO). In control experiments, 1 µM serotonin was replaced by 10 µM ADP. The samples
were analyzed by flow cytometry (FACSCalibur; Becton Dickinson, Franklin Lakes, NJ,
USA), and the data were expressed as the increase in phalloidin fluorescence induced by
either serotonin or ADP. For determination of serotonin-induced increases in platelet
cytosolic calcium levels (assessed by Fluo-4 fluorescence), blood was diluted 1 : 10 in
HEPES–Tyrode’s buffer and incubated for 30 min at 22 °C with 5 µM Fluo-4 (Invitrogen
Molecular Probes), 1 mM probenecid (Invitrogen Molecular Probes; to reduce extracellular
leakage of Fluo-4, as recommended by the manufacturer), and CD41–PE (DAKO) (as a
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platelet identifier). Platelet Fluo-4 fluorescence was monitored by flow cytometry before
and immediately after stimulation with 1 µM serotonin, using time as a parameter. In control
experiments, 1 µM serotonin was replaced by 10 µM ADP. The increase in Fluo-4 as a result
of increased intracellular calcium was calculated as the ratio of postactivation/preactivation
fluorescence. For both assays, data obtained before and after treatment were normalized, for
each dog, to the corresponding baseline values.
Statistics—Arterial injury scores were compared between groups by t-test. For all other
variables, two-factor ANOVA with replication followed by the Newman–Keuls test was applied.
As in protocol 1, data are reported as means ± SEMs, and P-values < 0.05 are considered to
be statistically significant.
Protocol 3: in vitro assessment of APD791
To provide further insights into the effect of APD791 on platelet-dependent clot formation
in models devoid of vascular smooth muscle, two in vitro post hoc experiments were
performed. The clot strength of human blood was determined in the thromboelastogram
(TEG) PlateletMapping System [19,20]. Paired aliquots of heparinized whole blood were
incubated with APD791 (100 nM) or vehicle for 10 min at 37 °C, and then placed in a TEG
pin-and-cup system with 10 µM serotonin, reptilase, and activated factor XIII (n = 3 paired
samples). The maximum amplitude of torsion (index of platelet-dependent clot strength) was
quantified for all samples. Platelet-mediated thrombosis under conditions of shear and in the
absence of exogenous serotonin was assessed in canine blood using the Platelet Function
Analyzer (PFA)-100 [19,21]. Aliquots of citrated blood (n = 3 pairs) were incubated with
APD791 (100 nM) or vehicle for 10 min at 37 °C, and then pipetted into collagen–ADP
cartridges. For each sample, the time (in seconds) required for the complete platelet-
mediated thrombotic occlusion of the membrane aperture was recorded.
Statistics—For both of the in vitro experiments, the primary endpoint (maximum
amplitude of torsion; closure time) was compared between APD791-treated and vehicle-
treated samples by paired t-test. Data are reported as means ± SEMs, and P-values < 0.05
are considered to be significant.
Results
Protocol 1: APD791 pretreatment
Hemodynamics and CBF—There were no differences in heart rate or mean arterial
pressure between saline-treated and APD791-treated groups at any time during the protocol
(that is, for mean arterial pressure, P = 0.508 between groups, and P = 0.540 for group–time
interaction; Fig. 3).
CBF was comparable between groups at baseline, averaging 12.9 ± 2.4 vs. 12.1 ± 1.7 mL
min−1 in dogs later assigned to receive saline vs. APD791 (P-value not significant).
Moreover, there was no difference in the severity of stenosis between the two cohorts: CBF
was reduced to 33% ± 2% vs. 34% ± 2% of baseline values upon application of the
constrictor.
Arterial damage—Arterial damage was consistently characterized by medial tearing and
dissection with minimal adventitial exposure (i.e. injury scores of 2–3; Fig. 2), with no
differences in mean injury score between control and APD791-treated dogs (2.7 ± 0.4 and
2.5 ± 0.2; P-value not significant).
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Plasma APD791 levels—As expected, plasma concentrations of APD791 were below the
threshold of quantitation in all dogs at baseline, and remained below the threshold of
detection for control dogs following administration of saline. In dogs assigned to receive
APD791, plasma APD791 levels showed a rapid and sustained increase, averaging 25.5 ±
4.1, 28.7 ± 4.6 and 31.2 ± 4.5 ng mL−1, respectively, at 10 min, 1.25 h and 2.25 h after the
start of treatment.
Vessel patency—As expected, all dogs exhibited spontaneous recurrent thrombosis
following coronary injury + stenosis, and no animals developed permanent thrombotic
occlusion during the 3-h observation period.
Vessel patency was maintained better in dogs pretreated with APD791: that is, zero flow
duration was reduced from 57 ± 14 min in controls to 1 ± 1 min in the APD791-treated
group (P < 0.01), whereas percentage flow–time area was increased from 28% ± 3% in
controls to 58% ± 3% in the cohort that received APD791 (P < 0.01; Fig. 4).
Protocol 2: APD791 ‘delayed’ treatment
Hemodynamics and CBF—As in protocol 1, heart rate and arterial pressure did not
differ between saline-treated and APD791-treated groups (for mean arterial pressure: P =
0.492 between groups, and P = 0.926 for group–time interaction; Fig. 5). In addition,
coronary flow was comparable between groups at baseline, and was reduced to 33–36% of
baseline in all dogs following placement of the constrictor (P-value not significant).
Arterial damage—As in protocol 1, all injured arterial segments displayed medial tearing
and dissection with minimal adventitial exposure (injury scores of 2–3; P-value not
significant between groups).
Plasma APD791 levels—Plasma APD791 concentrations were below the threshold of
quantitation in all dogs before randomization, remained undetectable in saline-treated dogs,
and averaged 20.4 ± 3.4 ng mL−1 at 1.5 h after the onset of treatment in animals that
received APD791.
Vessel patency—As in protocol 1, all animals developed CFVs (with no instances of
permanent thrombotic occlusion) following coronary injury + stenosis.
During the 1-h pretreatment phase, coronary patency was comparable in dogs later
randomized to receive APD791 vs. saline: mean percentage flow–time area was 26% ± 2%
vs. 21% ± 3%, and zero flow duration (expressed as a percentage of the 60-min pretreatment
period) averaged 24% ± 6% vs. 28% ± 8%, respectively (P-value not significant; Fig. 6). In
the saline-treated cohort, there was no significant change in patency during the final 2 h of
the protocol (following treatment) when compared with the pretreatment period. In contrast,
APD791 given 1 h after injury + stenosis evoked a significant increase in percentage flow–
time area (to 59% ± 4%) and a decrease in zero flow duration (to 0.2% ± 0.1%) during the
final 2 h of observation (P < 0.01 vs. pretreatment, and P < 0.01 vs. control for both
endpoints; Fig. 6).
Template bleeding times and blood ‘volumes’—Baseline values of template
bleeding time and shed blood ‘volume’ averaged 120 s and 35 mg, respectively, with no
differences in dogs later assigned to receive APD791 or saline. There was no significant
increase in bleeding following administration of APD791: at 1.5 h after the onset of
treatment, bleeding time was 105% ± 12% of baseline, and blood ‘volume’ averaged 88% ±
26% of baseline (Fig. 7).
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APD791 inhibition of ex vivo serotonin-stimulated platelet function—The
increase in platelet F-actin polymerization (as revealed by phalloidin staining) and platelet
intracellular calcium concentration (as reported by Fluo-4 fluorescence) in response to ex
vivo addition of serotonin averaged 90%–115% of baseline values in blood samples
collected at 1 h after the onset of thrombosis (immediately before randomization; Fig.
8A,B). Serotonin-stimulated platelet function remained unchanged following administration
of saline. In contrast, blood obtained from dogs following APD791 treatment displayed
significant inhibition of ex vivo serotonin-stimulated platelet F-actin formation (Fig. 8A) and
platelet intracellular calcium levels (Fig. 8B). Moreover, this ex vivo inhibition of platelet
activation in APD791-treated dogs was agonist-specific: that is, negative control
experiments showed no difference in ADP-stimulated phalloidin staining and Fluo-4
fluorescence between the APD791-treated and saline-treated groups (Fig. 8C,D).
Protocol 3: in vitro assessment of APD791
In vitro addition of APD791 was associated with a prolongation of PFA-100 closure time
(index of platelet-mediated thrombosis under conditions of shear) in canine blood samples,
and a reduction in the maximum amplitude of torsion (index of platelet-mediated clot
strength) in human blood samples (P < 0.01 and P < 0.05, respectively, vs. matched vehicle
controls; Fig. 9).
Discussion
We report here that the serotonin 5HT2A receptor antagonist APD791 improves arterial
patency in the canine model of recurrent coronary thrombosis, with efficacy being achieved
even when treatment is ‘delayed’ (i.e. initiated after the onset of recurrent thrombosis). In
addition, we provide novel ex vivo and in vitro data establishing that APD791 acts on
platelets (specifically, inhibits serotonin-stimulated increases in platelet F-actin
polymerization and intracellular calcium concentration, and attenuates platelet-dependent
clot strength and platelet-dependent thrombosis under conditions of shear), and show that its
effects are specific to serotonin. Finally, we show that APD791 was not associated with
increased bleeding.
Comparison with previous studies
Protocols 1 and 2 provide robust, quantitative evidence that APD791 improves flow–time
area and reduces the duration of total thrombotic occlusion, irrespective of whether
treatment is initiated before or after the onset of recurrent thrombosis. These data are
consistent with historical evidence that serotonin receptor antagonists (i.e. sarpogrelate)
have a favorable effect on vessel patency in thrombotic models [7,8,22–27]. However, the
novel aspect of the present study is the selectivity of APD791: in contrast to sarpogrelate,
which displays 10-fold and 100-fold selectivity for the for the 5HT2A vs. 5HT2c and 5HT2B
receptors, respectively [28], APD791 shows > 2000-fold selectivity for the 5HT2A subtype
and no detectable affinity for other G-protein-coupled receptors [9].
APD791 and patency: antiplatelet effect vs. inhibition of vasoconstriction?
We propose that APD791 evokes the observed, significant improvement in coronary patency
by blocking platelet 5HT2A receptors, thereby abrogating the proaggregatory effects of
serotonin released from activated platelets. In this regard, pharmacologic characterization of
APD791 has revealed that the agent has significant antiplatelet effects: that is, incubation of
platelet-rich plasma (canine and human) with APD791 and oral administration of APD791
to conscious dogs both attenuated serotonin-induced platelet aggregation as assessed ex vivo
by platelet aggregometry [9]. Additional evidence is provided in the current study: our ex
vivo assay conducted on blood obtained in protocol 2 following in vivo treatment (i)
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demonstrates that APD791 acts on circulating platelets and inhibits serotonin-stimulated
platelet activation; and (ii) establishes that the effects of APD791 are specific to serotonin.
This concept is further corroborated by our supplemental in vitro experiments showing that
incubation of whole blood with APD791 attenuates platelet-dependent thrombosis as
determined by both TEG and PFA-100 closure times. It is of note that the latter observation
of a prolonged closure time in APD791-treated aliquots was obtained in the absence of
exogenously added serotonin, thereby suggesting that serotonin released from activated
platelets contributed to the formation of the occlusive clot in collagen–ADP cartridges.
Although these data support a significant role for platelet inhibition, it could be argued that
the better maintenance of coronary patency achieved with APD791 may reflect blunting of
serotonin-induced vasoconstriction via inhibition of 5HT2A receptors on vascular smooth
muscle [10,29]. There is no question that, in arterial segments displaying endothelial
damage, serotonin is a potent vasoconstrictor [30]. Moreover, APD791 has been shown to
attenuate serotonin-induced constriction of isolated rabbit aortic rings (endothelium
removed) in a dose-dependent manner [9]. We cannot exclude the possibility that the
benefits of APD791 in our model are due in part to inhibition of serotonin-induced
vasoconstriction. In addition, because of differences in the concentrations of serotonin and
APD791 used in the platelet vs. vasoconstriction assays [9], we cannot extrapolate from
these data to speculate on the contribution of APD791-mediated attenuation of
vasoconstriction to the improved patency seen with APD791 in vivo. However, the in vitro
evidence of attenuated platelet-mediated thrombosis in models devoid of vascular smooth
muscle, and the fact that the cyclic flow variations seen in vivo following coronary injury +
stenosis are well-documented to reflect recurrent platelet-dependent thrombosis rather than
vasospasm [11–15,31], suggest that inhibition of serotonin-induced platelet aggregation
plays a major role in the improved patency achieved with APD791.
APD791 and bleeding
APD791 did not prolong template bleeding time or increase the ‘volume’ of blood shed
from the incision. This lack of effect of APD791 on bleeding may reflect the fact that
serotonin by itself is a weak stimulus for platelet activation; rather, serotonin augments
platelet activation induced by primary agonists (e.g. thrombin, ADP, and collagen) [5,6],
and thus inhibition of 5HT2A-mediated responses affects secondary amplification of platelet
activation–aggregation in a growing thrombus. Clinical studies are required to confirm
whether APD791 has a similar, benign bleeding profile in patients.
Summary, clinical relevance and future directions
There has been recent clinical interest in the use of sarpogrelate for the treatment of
intermittent claudication and ischemic stroke [32–34]. However, efforts to utilize earlier-
generation serotonin receptor antagonists as coronary antithrombotic agents have been
limited and largely unsuccessful [10,35], possibly owing to their lack of specificity for the
5HT2A receptor subtype and, in some instances, a concomitant increase in bleeding
[10,23,26]. The improved coronary patency achieved with APD791, and its lack of effect on
hemodynamics and bleeding, suggest that this potent and selective serotonin 5HT2A receptor
inhibitor may be effective in the treatment of unstable angina. In addition, our ex vivo assays
of serotonin-stimulated platelet function may be applied to monitor the in vivo efficacy of
APD791 in patients.
We did not, in our current protocols, assess whether any of the other complex molecular
effects of serotonin on platelet function (including including serotonin-induced GPIb-α
shedding and receptor-independent ‘serotonylation’-triggered platelet α-granule release
[36,37]) were altered by APD791 treatment. In addition, we cannot, on the basis of the
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present study, comment on the relative effectiveness of APD791 vs. agents that target cyclo-
oxygenase-1, GPIIb/IIIa or the ADP P2Y12 receptor. Nonetheless, our data raise the
possibility that targeted inhibition of the serotonin 5HT2A receptor may provide a
mechanistically distinct alternative or adjunct to currently approved antiplatelet therapies.
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Fig. 1.
Study design.
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Fig. 2.
Histologic section of damaged arterial segment. The micrograph shows medial tearing and
remnants of platelet-rich thrombus in the lumen.
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Fig. 3.
Protocol 1: hemodynamics.
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Fig. 4.
Protocol 1: vessel patency. (A) Original recordings of mean coronary flow following injury
+ stenosis from one control animal (showing the typical pattern of cyclic variations in flow)
and one dog pretreated with APD791. (B)Mean values of percentage flow–time area and
zero flow duration for control and APD791-treated groups. **P < 0.01 vs. control.
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Fig. 5.
Protocol 2: hemodynamics.
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Fig. 6.
Protocol 2: vessel patency. (A) Original recording of mean coronary flow from one animal,
obtained before and after administration of APD791. (B) Mean values of percentage flow–
time area and zero flow duration, measured before and after treatment, for control and
APD791-treated groups. †P < 0.01 vs. before treatment; **P < 0.01 vs. control.
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Fig. 7.
Protocol 2: template bleeding time and ‘volume’. Mean values of template bleeding time
and weight of shed blood for control and APD791-treated groups, measured before and after
treatment and normalized to baseline.
Przyklenk et al. Page 18
J Thromb Haemost. Author manuscript; available in PMC 2011 February 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 8.
Protocol 2: APD791 inhibition of ex vivo serotonin-stimulated platelet function. Mean
values of serotonin-stimulated phalloidin binding and Fluo-4 fluorescence (A, B) and ADP-
stimulated phalloidin binding and Fluo-4 fluorescence (C, D) for control and APD791-
treated groups, measured before and after treatment and normalized to baseline. **P < 0.01
vs. control.
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Fig. 9.
Protocol 3: effect of APD791 on in vitro platelet-dependent clot formation. Mean values of
clot strength [determined using the thromboelastogram (TEG) PlateletMapping System] and
closure time (assessed using the PFA-100) in whole blood aliquots incubated with APD791
[APD791 (+)] or vehicle [APD791 (−)]. *P < 0.05 and **P < 0.01 vs. matched APD791 (−)
aliquots.
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